In animals, PXR ablation inhibits diet-induced obesity, insulin resistance, and fatty liver disease in various rodent models, suggesting PXR antagonism as a putative anti-obesogenic and anti-diabetic pathway (104, 106). The gene discussed is NR1I2; the disease is obesity disorder.